Matica Bio Secures Adenovirus CDMO Contract with North American Institute
CHA Biotech’s U.S. Subsidiary, Matica Biotechnology, has entered into a contract development and manufacturing organization (CDMO) agreement with a large medical research institute in North America for adenovirus treatment. The agreement encompasses the entire pharmaceutical production lifecycle, from initial process development to commercial manufacturing adhering to current Good Manufacturing Practice (cGMP) standards.
Comprehensive CDMO Services
Under the terms of the contract, Matica Bio will provide end-to-end services, including cell line construction for adenovirus treatment, process and analytical development, quality testing, and cGMP production. The company leverages a variety of viral vector platforms and offers customized processes through its state-of-the-art CDMO facilities.
“Based on Matica Bio’s expertise in adenovirus technology, we will support treatments being developed by research institutes so that they can enter the clinical development stage,” said Paul Kim, CEO of Matica Bio.
Expanding Presence in the U.S. Cell and Gene Therapy Market
Matica Bio was established by CHA Biotech to participate in the U.S. Cell and gene therapy (CGT) CDMO market. The company completed construction of its production facilities in College Station, Texas, in 2022 and is actively securing new orders based on its proprietary cell line platform and process development capabilities.
While the contract partner and financial details remain undisclosed, industry analysts note that Matica Bio is currently focused on building its reference portfolio through initial orders rather than securing large-scale commercialization contracts.
Matica Bio’s Broader Collaborations
In addition to the recent adenovirus CDMO contract, Matica Bio is also collaborating with Cirsium Biosciences to enhance adeno-associated virus (AAV) manufacturing. This partnership integrates Cirsium’s plant-based AAV technology with Matica Bio’s analytical and downstream support, aiming to improve the efficiency and scalability of gene therapy production.
Matica Bio has independently developed a high-resolution ion-exchange chromatography (IEX) method for analyzing the ratio of empty and full AAV8 viral vector capsids, addressing a critical quality control challenge in gene therapy manufacturing.
Keep reading